image
Healthcare - Biotechnology - NASDAQ - IL
$ 0.9505
-22.1 %
$ 8.38 M
Market Cap
-3.17
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one XTLB stock under the worst case scenario is HIDDEN Compared to the current market price of 0.951 USD, XTL Biopharmaceuticals Ltd. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one XTLB stock under the base case scenario is HIDDEN Compared to the current market price of 0.951 USD, XTL Biopharmaceuticals Ltd. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one XTLB stock under the best case scenario is HIDDEN Compared to the current market price of 0.951 USD, XTL Biopharmaceuticals Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart XTLB

image
$2.2$2.2$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
451 K REVENUE
0.00%
-2.17 M OPERATING INCOME
-183.92%
-1.03 M NET INCOME
42.37%
-1.62 M OPERATING CASH FLOW
-128.85%
-844 K INVESTING CASH FLOW
-2058.54%
1.45 M FINANCING CASH FLOW
0.00%
289 K REVENUE
78.40%
-812 K OPERATING INCOME
-6.28%
-553 K NET INCOME
21.45%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet XTL Biopharmaceuticals Ltd.
image
Current Assets 1.34 M
Cash & Short-Term Investments 1.14 M
Receivables 99 K
Other Current Assets 98 K
Non-Current Assets 7.21 M
Long-Term Investments 14 K
PP&E 187 K
Other Non-Current Assets 7.01 M
13.37 %81.98 %Total Assets$8.6m
Current Liabilities 2.21 M
Accounts Payable 196 K
Short-Term Debt 138 K
Other Current Liabilities 1.87 M
Non-Current Liabilities 908 K
Long-Term Debt 0
Other Non-Current Liabilities 908 K
6.29 %4.43 %60.13 %29.15 %Total Liabilities$3.1m
EFFICIENCY
Earnings Waterfall XTL Biopharmaceuticals Ltd.
image
Revenue 451 K
Cost Of Revenue 448 K
Gross Profit 3 K
Operating Expenses 2.18 M
Operating Income -2.17 M
Other Expenses -1.14 M
Net Income -1.03 M
500k500k00(500k)(500k)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)451k(448k)3k(2m)(2m)1m(1m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.67% GROSS MARGIN
0.67%
-481.60% OPERATING MARGIN
-481.60%
-227.72% NET MARGIN
-227.72%
-18.90% ROE
-18.90%
-12.01% ROA
-12.01%
-29.75% ROIC
-29.75%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis XTL Biopharmaceuticals Ltd.
image
00(200k)(200k)(400k)(400k)(600k)(600k)(800k)(800k)(1m)(1m)(1m)(1m)(1m)(1m)(2m)(2m)(2m)(2m)(2m)(2m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -1.03 M
Depreciation & Amortization 199 K
Capital Expenditures -54 K
Stock-Based Compensation 264 K
Change in Working Capital 189 K
Others -1.17 M
Free Cash Flow -1.67 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets XTL Biopharmaceuticals Ltd.
image
XTLB has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership XTL Biopharmaceuticals Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
XTL Names Mr. Noam Band as its New Chief Executive Officer Brings a Wealth of Managerial Experience and Track Record RAMAT GAN, ISRAEL, April 07, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”) announced today the appointment of Noam Band as the Company's new Chief Executive Officer. globenewswire.com - 2 months ago
XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 Million expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company  developing and powering an IP based platform for AI & BI Applications at scale Completed a Private Placement of $1.5 Million   RAMAT GAN, ISRAEL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- August 14, 2024, XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today it has completed the acquisition of THE SOCIAL PROXY Ltd. globenewswire.com - 10 months ago
XTL Entered Definitive Agreement to Acquire The Social Proxy expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company  developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, June 05, 2024 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (the “Company” or  “XTL”) announced today it has entered into a definitive share purchase agreement with the current shareholders of THE SOCIAL PROXY Ltd. globenewswire.com - 1 year ago
XTL To Aquire The Social Proxy expands its IP portfolio to AI Web Data The Social Proxy is a web data AI company developing and powering an IP based platform for AI & BI Applications at scale Secured $1.5 Million in a Private Placement RAMAT GAN, ISRAEL, March 20, 2024 (GLOBE NEWSWIRE) --  XTL Biopharmaceuticals Ltd. (the “Company” or “XTL”) announced today that it has entered into a binding term sheet with THE SOCIAL PROXY Ltd. globenewswire.com - 1 year ago
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren's syndrome, or SS, today announced that the Company received a written notification (the "Notice") from the Nasdaq Stock Market LLC (“Nasdaq”) on October 18, 2023, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Rules for continued listing on the Nasdaq. globenewswire.com - 1 year ago
XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in Israel Ramat Gan, Israel, Oct. 20, 2023 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTLB.TA) ("XTL" or the "Company"), a clinical stage biopharmaceutical company whose main assets consists of an IP portfolio relating to hCDR1 for the treatment of systemic lupus erythematosus, or SLE, and Sjögren's syndrome, or SS, today addressed the status of the Company's continued and uninterrupted activity in Israel against the background of the recent severe terrorist attack in the south of the country and the subsequent declaration of war by the Israeli government against the Hamas terrorist organization. globenewswire.com - 1 year ago
XTLB Stock Price Increases Over 100% Pre-Market: Why It Happened The stock price of XTL Biopharmaceuticals (NASDAQ: XTLB) has increased by over 100% pre-market. This is why it happened. pulse2.com - 4 years ago
8. Profile Summary

XTL Biopharmaceuticals Ltd. XTLB

image
COUNTRY IL
INDUSTRY Biotechnology
MARKET CAP $ 8.38 M
Dividend Yield 0.00%
Description XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Contact 5 Badner Street, Ramat Gan, 5218102 https://www.xtlbio.com
IPO Date Sept. 1, 2005
Employees 10
Officers Mr. Itay Weinstein CPA Chief Financial Officer Mr. Noam Band Chief Executive Officer